GeoVax Labs has completed enrollment for a Phase I/II study assessing the safety and immunogenicity of its experimental therapeutic DNA/MVA vaccine in HIV-positive patients whose infections can be controlled with oral drugs. The company could proceed to an early-stage trial of the vaccine with conventional care in young adults, Chief Scientific Officer Harriet Robinson said.

Related Summaries